Summary:
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet NeedsSAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been treated in the company’s Phase 2a trial evaluating MET409 (50 mg) in...
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported ...
A look at the shareholders of Metacrine, Inc. ( NASDAQ:MTCR ) can tell us which group is most powerful. Insiders often...
In this article you are going to find out whether hedge funds think Metacrine, Inc. (NASDAQ:MTCR) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the following December investor conferences: * Piper Sandler 32nd Annual Virtual Healthcare Conference (fireside chat) being held December 1-3...
Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH $85 Million Initial Public Offering Completed SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported recent business highlights and third quarter 2020 financial results.“2020 has been a transformational ye...
New Enterprise Associates revealed a large investment in biopharmaceutical company Metacrine. Baker Brothers Advisors disclosed an initial position in oncology-focused biopharmaceutical firm of Prelude.
New Data Support Robust, Sustained FXR Activation by MET409 in Patients with NASH and Demonstrate Predictability of Liver Fat Reductions as Early as Week 4 of TreatmentSAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that two posters highlighting new data on the company’s lead clinical candidat...